802. Chemical Biology and Experimental Therapeutics: Poster III

Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Development of Humanized Antibodies Against Vasoactive Intestinal Polypeptide for Increased T Cell Anti-Leukemia Activity

Discovery of UBE2B and RNF144b As Potential Candidates for Selective Degradation of NPM1c in AML

Novel MET Inhibitors Provide a Therapeutic Opportunity for AML By Overcoming the Protective Action of the Bone Marrow Niche

Preclinical Efficacy of Decoy-Resistant IL-18 in Hematological Malignancies

Targeting Metabolism to Restore Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Preclinical Insights from Zebrafish Models

The Nanoparticle-Mediated Delivery of Therapeutic Sirnas Targeting the KMT2A::Afdn Fusion Gene in AML